Three Essential Points When Investing In A Genomics Startup Genomics is rapidly evolving – and that means there are a plethora of investment opportunities available. However, not all genomics companies offer the same long-term value. A wise investor can tell the difference between a company that just looks good now and one that is built to last. The genomics industry will not look like it does today in five years. In 15 years, it will be radically different. Just look how far we have already advanced.
Genomics testing will help account care organizations (ACOs) and other forward-thinking healthcare providers create outreach programs that will improve member health and lower costs. What these organizations need is a way for patients to have their DNA tested efficiently and cost effectively.
From large, well-established companies to relative newcomers, health insurance companies found it difficult to be profitable in 2015. However, companies with the insight to invest in genomics can begin to reap the rewards now and are setting themselves up for long-term benefits.
Genomics will revolutionize medicine. Targeted genetic treatments are already being developed for certain cancers. As we learn more about our DNA and how diseases are related to specific genes, diagnostic testing and medications will evolve rapidly.
Treating patients is a calling for most medical practitioners, whose profession demands highest standard of ethics in every aspect. Communicating health information to a patient and family who already feel vulnerable is by far the core and critical aspect in a physician’s day to day operation. In case of a suspected health condition, a Physician typically educates and advises the patient before ordering a test. In case of a confirmed condition, both engage in a management plan to keep the condition under control. This is a practice well understood by patients, providers and insurance companies.
The study of the human genome has come a long way since its first successful sequencing 15 years ago at a cost in excess of a $1,000,000. The curiosity of knowing your own DNA even caught up with Apple’s founder, Steve Jobs, who paid $100K for sequencing. Since then, enthusiasts and researchers have responded to growing demand and are now making a personal genome available for a few hundred dollars. As with all technologies, quality has become the differentiator and a basic genome offers an inexpensive non-clinical peak at anyone’s DNA. While there is much debate over whether such marginally reliable information is helpful, as it could create unnecessary anxiety in individuals and families, the demand is strong as indicated by the growth of the consumer genomics industry.